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ABSTRACT 
A simple, accurate, precise and rapid stability indicating RP-HPLC method was developed and validated for the analysis of 
Olanzapine in marketed formulation. Analysis was performed on a C-18 (250mm x 4.60mm, 5 µm) column as stationary phase and 
using mobile phase which was Potassium di-hydrogen phosphate Buffer (pH 6): Acetonitrile (60:40) (v/v) at a flow rate of 1ml/min 
with UV detection at 258 nm at constant room temperature. The injection volume was 20 µl and the chromatographic runtime of 5 
min was used. Proposed method was found to be linear in the range of 5-25 μg/ml with the correlation coefficient 0.998. The 
validation and the reliability of proposed method were assessed by recovery study. The recovery of added standards (80%, 100% 
120%) was ranging from 99.58% - 100.50%. The robustness of developed method was checked by changing temperature, flow rate 
and mobile phase ratio. 
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INTRODUCTION: 
The quantitative estimation of the active constituents is 
an integral part of developing and manufacturing process 
of pharmaceutical dosage forms. There is a need for 
development of better and reliable methods for the 
estimation of pharmaceutical dosage form. The official 
methods for the analysis of active ingredients of 
formulations are few and the most of the methods 
available for the analysis of active ingredients are 
applicable only after prior separation that involves 
tedious and time-consuming procedures. 
Literature survey reveals that lesser method 
development of RP-HPLC method for the determination 
of Olanzapine in bulk forms or other pharmaceutical 
dosage form has been reported. Literature survey also 





, Ultra Performance Liquid Chromatography 
(RP-UPLC) technique
3
 were also been developed for the 
determination of Olanzapine. 
Therefore in this study an attempt is made to develop 
RP-HPLC methods for the method development of the 
drug in pharmaceutical formulations. Hence, the 
proposed method is simple, fast, accurate, precise and 
reproducible and can be applied for routine quality 
control analysis of drugs in bulk or in pharmaceutical 
formulations. 
MATERIALS AND METHODS: 
Olanzapine was made available from Bioplus, Bangalore 
(Purity 99.8%). Methanol (AR Grade) was purchased 
from Merck Ltd., India were used for sample 
preparation. Acetonitrile (HPLC), Methanol (HPLC) and 
Water (HPLC) were purchased from Merck Ltd., India 
used for the preparation of mobile phase. Potassium di-
hydrogen phosphate, Ortho Phosphoric acid and Triethyl 
amine used for the preparation of buffer. Olanzapine 
marketed formulation (Oleanz-10 containing 10mg of 
Olanzapine which was manufactured by Sun Pharma, 
Mumbai, India) was procured from a local pharmacy. 
Chromatographic separation was performed on Waters 
HPLC system. The output signal was monitored and 
processed using empowers software. The 
chromatographic column used was C-18 (250mm x 
4.60mm, 5µm). 
Analytical Method Development by RP-HPLC: 
Mobile Phase selection was done by selecting numbers 
of mobile phase in different ratio. Taking into 
consideration of the system suitability parameter, the 
mobile phase found to be most suitable for analysis was 
Buffer (1.75 gm KH2PO4 in 1000 ml water add 1 ml of 
TEA adjust the pH 6 with OPA): Acetonitrile (60:40). 
Solubility and FTIR of standard Olanzapine drug was 
performed.  
Selection of wavelength was done by making a solution 
of 10µg/ml of standard Olanzapine drug and scanned 
over UV range (200-400nm). Selection of separation 
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variable was done by preparing Olanzapine solution in 
different mobile phase and chromatograph was recorded 
by using different column at different chromatographic 
condition like different flow rate and temperature. 
Considering the theoretical facts and after several trials 
separation variables were selected which were constant 
during whole experiment. Separation variables were set 
and mobile phase was allowed to saturate the column at 
1.0 ml/min. After complete saturation of column, three 
replicates of working standard of Olanzapine 10 µg/ml 
was injected separately. Peak report and column 
performance report were recorded for all chromatogram 
checking the system suitability parameters. Different 
working standard solutions were made of concentrations 
5, 10, 15, 20, 25 µg/ ml using the diluents Water: ACN 
(50:50 v/v). Standard drug solutions were injected 3 
times and the mean peak area of drug was calculated and 
plotted against the concentration of the drug. The 
regression equation was found out by using this 
calibration curve. A solution was made containing 10 
µg/ml of Olanzapine from marketed formulation and the 
amounts of Olanzapine in tablet formulation were 
calculated by extrapolating the value of area from the 
calibration curve. Analysis procedure was repeated three 
times with tablet formulation.  
Validation: Linearity was observed by plotting the 
calibration curve after analysis of five different (from 5 
to 25 µg/ ml) concentrations and areas for each 
concentration were recorded three times, and mean area 
was calculated. The regression equation and correlation 
coefficient of curve were noted and the response ratio 
(response factor) was found. 
Recovery studies were performed to validate the 
accuracy of developed method. To preanalysed sample 
solution, a definite concentration of standard drug (80%, 
100%, and 120%) was added and then its recovery was 
analyzed. 
Precision was observed by repeatability and intermediate 
precision (Intra-day Precision, Inter-day Precision 
Analyst to Analyst). Standard dilutions were prepared 
and three replicates of each dilution were analyzed in 
different days and by different analysts. Robustness was 
performed by altering the pH, temperature and 
concentration of the mobile phase. 
RESULTS AND DISCUSSION: 
Olanzapine was yellow powder with melting point 195
 
o
C. Solubility study shows that Olanzapine was freely 
soluble in acetonitrile, 0.1 N HCl, benzene, methanol, 
slightly soluble in ethyl alcohol and insoluble in water, 
0.1 N NaOH, phosphate buffer  pH 7.4. The 
interpretation by FTIR shows that the drug was 


















 and 1139.06 cm
-1
. 
Maximum absorbance was found at λmax 258.00 nm. 
Taking into consideration the system suitability 
parameter the mobile phase found to be most suitable for 
analysis was Buffer (1.75 gm KH2PO4 in 1000 ml water 
add 1 ml of TEA adjust the pH 6 with OPA): 
Acetonitrile (60:40). The separation variables were set at 
flow rate 1ml/min, wavelength at 258 nm, the injection 
volume was 20 µl and the chromatographic runtime of 5 
min was used at room temperature. The system 
suitability parameters study was done in three replicates 
and the mean was calculated; retention time 3.476 min, 
theoretical plate 3077.333 and tailing factor 1.176667. 
An assay of marketed formulation was performed and 
mean reading of three batch of formulation was 10.076 
mg. The validation and the reliability of proposed 
method were assessed by recovery study. The recovery 
of added standards 80%, 100% 120% was ranging from 
99.56%, 100.10% and 90.75% respectively. By the 
Repeatability study the amount of Olanzapine in 
marketed formulation was found 9.95mg i.e. 99.50%. By 
Intra-day Precision after 6 hr the amount of Olanzapine 
in marketed formulation was found to be 98.97%, by 
Inter-day Precision the amount of Olanzapine in 
marketed formulation was found to be 97.10% and by 
Analyst to Analyst precision the amount of Olanzapine 
in marketed formulation was found to be 99.84%. The 
robustness of developed method by altering the pH, 
temperature and concentration of the mobile phase were 
made and the method capacity remains unaffected.
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